EP3062795A4 - Formes cristallines de composés thérapeutiques et utilisations de celles-ci - Google Patents

Formes cristallines de composés thérapeutiques et utilisations de celles-ci Download PDF

Info

Publication number: EP3062795A4
Authority: EP; European Patent Office
Prior art keywords: crystalline forms; therapeutic compounds; therapeutic; compounds; crystalline
Prior art date: 2013-11-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP14857110.2A

Other languages

German (de)

English (en)

Other versions

EP3062795A1 (fr

Inventor

Elizabeth ENLOW

Minh Ngoc Nguyen

Winston Z. ONG

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kala Bio Inc

Original Assignee

Kala Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-11-01

Filing date

2014-11-03

Publication date

2017-05-31

2014-02-20 Priority claimed from US14/184,886 external-priority patent/US9353123B2/en

2014-11-03 Application filed by Kala Pharmaceuticals Inc filed Critical Kala Pharmaceuticals Inc

2016-09-07 Publication of EP3062795A1 publication Critical patent/EP3062795A1/fr

2017-05-31 Publication of EP3062795A4 publication Critical patent/EP3062795A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dispersion Chemistry (AREA)
Physics & Mathematics (AREA)
Biomedical Technology (AREA)
Nanotechnology (AREA)
Optics & Photonics (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)

EP14857110.2A 2013-11-01 2014-11-03 Formes cristallines de composés thérapeutiques et utilisations de celles-ci Withdrawn EP3062795A4 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361898741P	2013-11-01	2013-11-01
US14/184,886 US9353123B2 (en)	2013-02-20	2014-02-20	Therapeutic compounds and uses thereof
PCT/US2014/063630 WO2015066584A1 (fr)	2013-11-01	2014-11-03	Formes cristallines de composés thérapeutiques et utilisations de celles-ci

Publications (2)

Publication Number	Publication Date
EP3062795A1 EP3062795A1 (fr)	2016-09-07
EP3062795A4 true EP3062795A4 (fr)	2017-05-31

Family

ID=53005242

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP14857110.2A Withdrawn EP3062795A4 (fr)	2013-11-01	2014-11-03	Formes cristallines de composés thérapeutiques et utilisations de celles-ci

Country Status (5)

Country	Link
EP (1)	EP3062795A4 (fr)
JP (2)	JP6426195B2 (fr)
AU (1)	AU2014341966B2 (fr)
CA (2)	CA3109285A1 (fr)
WO (1)	WO2015066584A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3062795A4 (fr) *	2013-11-01	2017-05-31	Kala Pharmaceuticals, Inc.	Formes cristallines de composés thérapeutiques et utilisations de celles-ci
JP7108681B2 (ja)	2017-08-11	2022-07-28	アモーレパシフィックコーポレーション	（ｒ）‐ｎ‐［１‐（３，５‐ジフルオロ‐４‐メタンスルホニルアミノ‐フェニル）‐エチル］‐３‐（２‐プロピル‐６‐トリフルオロメチル‐ピリジン‐３‐イル）‐アクリルアミドを含む医薬組成物
KR102518632B1 (ko)	2018-04-18	2023-04-06	(주)아모레퍼시픽	(r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물
WO2020179837A1 (fr)	2019-03-04	2020-09-10	Ricoh Company, Ltd.	Appareil et procédé de traitement de coopération
GB201915447D0 (en) *	2019-10-24	2019-12-11	Johnson Matthey Plc	Polymorphs of avapritinib and methods of preparing the polymorphs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014130612A1 (fr) *	2013-02-20	2014-08-28	Kala Pharmaceuticals, Inc.	Composés thérapeutiques et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK288378B6 (sk) *	1999-02-10	2016-07-01	Astrazeneca Ab	Použitie chinazolínových derivátov ako inhibítorov angiogenézy
PT1474420E (pt) *	2002-02-01	2012-05-10	Astrazeneca Ab	Compostos de quinazolina
CL2004000409A1 (es) *	2003-03-03	2005-01-07	Vertex Pharma	Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
GB0310401D0 (en) *	2003-05-07	2003-06-11	Astrazeneca Ab	Therapeutic agent
GB0330002D0 (en) *	2003-12-24	2004-01-28	Astrazeneca Ab	Quinazoline derivatives
WO2006040526A1 (fr) *	2004-10-12	2006-04-20	Astrazeneca Ab	Derives de quinazoline a utiliser contre le cancer
EP3062795A4 (fr) *	2013-11-01	2017-05-31	Kala Pharmaceuticals, Inc.	Formes cristallines de composés thérapeutiques et utilisations de celles-ci

2014
- 2014-11-03 EP EP14857110.2A patent/EP3062795A4/fr not_active Withdrawn
- 2014-11-03 CA CA3109285A patent/CA3109285A1/fr not_active Abandoned
- 2014-11-03 CA CA2928665A patent/CA2928665A1/fr not_active Abandoned
- 2014-11-03 AU AU2014341966A patent/AU2014341966B2/en not_active Ceased
- 2014-11-03 WO PCT/US2014/063630 patent/WO2015066584A1/fr active Application Filing
- 2014-11-03 JP JP2016552430A patent/JP6426195B2/ja not_active Expired - Fee Related
2018
- 2018-10-24 JP JP2018199872A patent/JP2019038824A/ja active Pending

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014130612A1 (fr) *	2013-02-20	2014-08-28	Kala Pharmaceuticals, Inc.	Composés thérapeutiques et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAIRA: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, January 1998 (1998-01-01), pages 163 - 208, XP008166276, ISSN: 0340-1022 *
See also references of WO2015066584A1 *

Also Published As

Publication number	Publication date
AU2014341966A1 (en)	2016-05-12
AU2014341966B2 (en)	2017-08-17
JP2016535779A (ja)	2016-11-17
CA3109285A1 (fr)	2015-05-07
CA2928665A1 (fr)	2015-05-07
EP3062795A1 (fr)	2016-09-07
WO2015066584A1 (fr)	2015-05-07
JP6426195B2 (ja)	2018-11-21
JP2019038824A (ja)	2019-03-14

Publication	Publication Date	Title
IL287516A (en)	2021-12-01	Medicinal uses of empagliflozin
HRP20190101T1 (hr)	2019-03-08	Terapeutske uporabe empagliflozina
EP3046563A4 (fr)	2017-02-15	Composés substitués d'aminopyrimidine et procédés d'utilisation
EP3019483A4 (fr)	2017-01-11	Composés thérapeutiquement actifs et leurs méthodes d'utilisation
EP3062618A4 (fr)	2017-07-12	Formes cristallines de composés thérapeutiques et leurs utilisations
EP3073999A4 (fr)	2017-03-22	Forme cristalline i d'ibrutinib
EP3027193A4 (fr)	2017-04-26	Composés thérapeutiquement actifs et leurs méthodes d'utilisation
HK1213818A1 (zh)	2016-07-15	依帕列淨的治療用途
EP3083589A4 (fr)	2017-05-24	Composés pipéraziniques substitués et leurs procédés d'utilisation
PL2981271T3 (pl)	2019-05-31	Zastosowania terapeutyczne empagliflozyny
EP2983681A4 (fr)	2017-01-04	Compositions thérapeutiques et leurs utilisations
EP3038622A4 (fr)	2017-04-12	Composés hétérocycliques et leurs méthodes d'utilisation
EP3019477A4 (fr)	2017-01-11	Composés hétérocycliques et leurs procédés d'utilisation
EP3054974A4 (fr)	2017-06-14	Composés interagissant avec le glycane et procédés d'utilisation
EP3055281A4 (fr)	2017-09-20	Préparation de dérivés d'hydroxy-benzylbenzène
EP3036226A4 (fr)	2017-04-05	Inhibiteurs de la 12/15-lipoxygénase- humaine
EP3068416A4 (fr)	2017-08-09	Composés thérapeutiques issus du kava et leurs procédés d'utilisation
EP3049079A4 (fr)	2017-04-05	Formes solides de ceftolozane
EP3050881A4 (fr)	2017-03-22	Nouveau dérivé d'a-naphtylurée et son application médicale
EP3027182A4 (fr)	2017-04-12	Nouveau matériau de cuivre-cystéamine et procédés d'utilisation
EP3062795A4 (fr)	2017-05-31	Formes cristallines de composés thérapeutiques et utilisations de celles-ci
EP3104869A4 (fr)	2017-11-15	Traitement de la douleur
EP3027607A4 (fr)	2017-02-22	Composés hétéroaryle substitués et procédés d'utilisation
EP2986309A4 (fr)	2017-03-08	Composés peptidiques et leurs procédés de fabrication et d'utilisation
EP3509421A4 (fr)	2020-05-20	Formes cristallines de composés thérapeutiques et leurs utilisations

Legal Events

Date	Code	Title	Description
2016-08-05	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-09-07	17P	Request for examination filed	Effective date: 20160601
2016-09-07	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-09-07	AX	Request for extension of the european patent	Extension state: BA ME
2017-02-08	DAX	Request for extension of the european patent (deleted)
2017-05-31	A4	Supplementary search report drawn up and despatched	Effective date: 20170504
2017-05-31	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 9/10 20060101ALI20170426BHEP Ipc: C07D 493/10 20060101ALI20170426BHEP Ipc: A61K 31/517 20060101AFI20170426BHEP
2017-11-03	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1228278 Country of ref document: HK
2018-06-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2018-07-04	17Q	First examination report despatched	Effective date: 20180604
2019-04-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2019-05-22	18D	Application deemed to be withdrawn	Effective date: 20181215
2024-05-31	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1228278 Country of ref document: HK